George Yancopoulos, Regeneron

Re­gen­eron's lat­est ge­net­ics dis­cov­ery hooks As­traZeneca — now all-in on de­vel­op­ing small mol­e­cules for obe­si­ty

Just weeks af­ter its wide­ly laud­ed ge­net­ics re­search arm tagged a promis­ing new tar­get for obe­si­ty, Re­gen­eron has signed up an in­dus­try heavy­weight to col­lab­o­rate with on de­vel­op­ing new drugs that can po­ten­tial­ly act as a game-chang­er in what has proven to be a tough field for de­vel­op­ers.

The Re­gen­eron Ge­net­ics Cen­ter pub­lished a pa­per in Sci­ence at the be­gin­ning of this month high­light­ing how their work se­quenc­ing the genomes of 650,000 peo­ple high­light­ed how peo­ple with at least 1 in­ac­tive copy of the GPR75 gene weighed on av­er­age 12 pounds less than the rest of the pop­u­la­tion with a 54% re­duc­tion in risk of obe­si­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.